Opinion|Videos|November 4, 2024
Protocol Development for Administration and AE Management of Bispecifics
Panelists discuss how they developed their protocols for administering bispecific antibodies and monitoring and managing associated adverse events.
Advertisement
Video content above is prompted by the following:
How did you develop your administration and adverse event monitoring and management protocols?
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
A Japanese study found favorable sensitivity and specificity for recurrence of melanoma based on presence of melanoma-specific markers in circulating tumor DNA.
Theodore Wagener, PhD, of Ohio State discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.
"AI will not replace oncologists; it will help interpret complex data and design more precise, adaptive, personalized cancer treatment," the authors write.
The phase 2 NRG-BR002 failed to improve outcomes with targeted radiotherapy to oligometastases; the phase 3 portion will not proceed.
ER status and HER2DX score predict complete response to neoadjuvant THP in HER2-positive breast cancer, guiding smarter, less intensive chemo selection.
VIR-5500 and [²¹²Pb]PSV359 received FDA fast track designations for prostate cancer and solitary fibrous tumors, respectively.
The approval of the adjuvant atezolizumab combination in dMMR colon cancer is supported by the phase 3 ATOMIC trial.
During a roundtable event, Amit R. Mehta, MD, and participants discussed treatment selection for a patient with immune thrombocytopenia whose quality of life is impaired even as her platelet count recovers.
Advertisement
Advertisement